Status:
COMPLETED
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
Eligibility Criteria
Inclusion
- Patients must be diagnosed with partial epilepsy and have experienced at least 2 partial seizures (simple partial, complex partial or partial seizure with secondary generalization) in the past year with one in the past 6 months.
Exclusion
- Treatable causes of seizures, for example identified etiologies including metabolic, neoplastic or active infectious origin.
- Primary generalized seizures.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT00280059
Start Date
August 1 2006
End Date
April 1 2010
Last Update
January 28 2021
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bruges, Belgium, 8000
2
Pfizer Investigational Site
Brussels, Belgium, 1070
3
Pfizer Investigational Site
Leuven, Belgium, 3000
4
Pfizer Investigational Site
Plovdiv, Bulgaria, 4000